Spit and blood may predict who benefits from lung cancer immunotherapy
NCT ID NCT07163507
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at sputum and blood samples from 50 adults with advanced non-small cell lung cancer who are starting immunotherapy. Researchers want to find immune cell changes that could predict which patients will respond well to treatment. The goal is to better understand the immune system's role in fighting lung cancer and improve future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
university hospital, Tours
Tours, 37044, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Exercise as medicine: tailored workouts may rebuild strength after cancer
- Family support may be key to easing lung cancer surgery stress
- Can a drop of blood predict disease years before it strikes?
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?